This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Unique HealthShares ETFs Deserve a Look

Last week, a company called XShares Advisors launched the first five of what will be many more ETFs focused on narrow subsectors within the health care sector. The product line is aptly called HealthShares.

The first five:

  • HealthShares Cardio Devices (HHE)
  • HealthShares Diagnostic (HHD)
  • HealthShares Emerging Cancer (HHJ)
  • HealthShares Enabling Technologies (HHV)
  • HealthShares Patient Care Services (HHB)
  • Above anything else, these are unique. You can decide for yourself whether "unique" means they are worthy of your money, but on first glance, I would not idly dismiss them.

    There are a couple of structural differences that could offer better returns but are also likely to increase volatility. First is that most of the funds have 22-25 equally weighted holdings. That the funds have so few holdings should not be a surprise. How many "enabling tech" companies can there be?

    The other important thing is the market cap restrictions; no companies larger than $15 billion. This is important. Chances are a stock like Pfizer (PFE - Get Report) could be a justified inclusion in most of the funds, but it is unlikely that a mega-cap like that could be a proxy for any of them.

    By excluding large companies, HealthShares give holders of its funds the chance to really participate in the narrowness of these themes. While I should note that there are some fuzzy exceptions to the $15 billion number, the important thing is that Merck (MRK) and Pfizer will not take up 20% of each fund.
    1 of 2

    Check Out Our Best Services for Investors

    Action Alerts PLUS

    Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

    Product Features:
    • $2.5+ million portfolio
    • Large-cap and dividend focus
    • Intraday trade alerts from Cramer
    Quant Ratings

    Access the tool that DOMINATES the Russell 2000 and the S&P 500.

    Product Features:
    • Buy, hold, or sell recommendations for over 4,300 stocks
    • Unlimited research reports on your favorite stocks
    • A custom stock screener
    Stocks Under $10

    David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

    Product Features:
    • Model portfolio
    • Stocks trading below $10
    • Intraday trade alerts
    14-Days Free
    Only $9.95
    14-Days Free
    Dividend Stock Advisor

    David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

    Product Features:
    • Diversified model portfolio of dividend stocks
    • Updates with exact steps to take - BUY, HOLD, SELL
    Trifecta Stocks

    Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

    Product Features:
    • Model Portfolio
    • Intra Day Trade alerts
    • Access to Quant Ratings
    Real Money

    More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

    Product Features:
    • Access to Jim Cramer's daily blog
    • Intraday commentary and news
    • Real-time trading forums
    Only $49.95
    14-Days Free
    14-Days Free
    SMH $51.89 0.37%
    PFE $33.57 0.51%
    AAPL $93.24 -0.41%
    FB $117.81 -0.21%
    GOOG $701.43 0.82%


    Chart of I:DJI
    DOW 17,660.71 +9.45 0.05%
    S&P 500 2,050.63 -0.49 -0.02%
    NASDAQ 4,717.0940 -8.5450 -0.18%

    Free Reports

    Top Rated Stocks Top Rated Funds Top Rated ETFs